New way to treat cancer.
Frezent is developing first-in-class biologic inhibitors of cancer metabolism. Our aim is to eliminate residual cancer cells and prevent tumor relapse.
We set a high bar to deliver a true clinical value.
Ensure complete response
Eliminate dividing and non-dividing (dormant) cancer cells to ensure complete drug response.
Design biologics for low toxicity
Optimize antibodies to selectively block cancer and limit toxicity to healthy organs.
Treat residual disease early
Integrate treatment targeting residual dormant cancer cell with standard of care to prevent late relapse.
Improve patient survival by preventing cancer progression.
20 million
New cancer cases annually worldwide
50%
Estimated risk of disease progression and mortality
“We want to give cancer survivors the confidence that their cancer won’t return, and to bring them and their families peace of mind.”
-Dr. Natasha Shtraizent, PhD, Co-founder and CEO of Frezent
Our team and partners
A multidisciplinary team of founders with deep scientific expertise, supported by an advisory board of proven leaders across biotech, business, and oncology therapeutics.
We partner with leading hospitals and work with key opinion leaders in oncology.
Frezent is supported by SOSV, New York Ventures (Empire State Development) and funding from NSF-SBIR grant.
We have joined accelerator programs to catalyze our journey from bench toward clinic.
Join us
Reach out for partnerships, investment opportunities, or general inquiries.